Vivatides Therapeutics

Vivatides Therapeutics is a private biotechnology company developing extrahepatic RNA-targeting therapeutics designed to extend the reach of RNA medicines beyond the liver. The company is building a delivery platform that supports both small interfering RNA and antisense oligonucleotide approaches, with a focus on ligand conjugation, delivery efficiency, tissue specificity, and safety. Vivatides is advancing multiple preclinical programs and positions itself around chronic diseases and other indications that have been difficult to address with conventional liver-directed RNA delivery. The company operates across the United States and China and has recently raised Series A financing to expand its platform, pipeline, and global R&D organization.